Thr709

Site Information
PKRLGAHtP______ SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 451149

In vivo Characterization
Methods used to characterize site in vivo:	electrophoretic mobility shift ( 4 ) , mass spectrometry ( 1 , 2 , 3 , 4 ) , mutation of modification site ( 4 )
Disease tissue studied:	breast cancer ( 3 ) , breast ductal carcinoma ( 3 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, surrounding tissue ( 2 ) , breast cancer, triple negative ( 2 , 3 ) , neuroblastoma ( 1 )
Relevant cell line - cell type - tissue:	breast ( 2 , 3 ) , CHO (fibroblast) [EphB1 (human), transfection] ( 4 ) , CLB-Bar ( 1 )

References
1	Borenäs M, et al. (2024) ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition. Proc Natl Acad Sci U S A 121, e2315242121 38154064 Curated Info
2	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
3	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
4	Standen CL, et al. (2003) The neuronal adaptor protein Fe65 is phosphorylated by mitogen-activated protein kinase (ERK1/2). Mol Cell Neurosci 24, 851-7 14697653 Curated Info